A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651

A. Argiris, M. Gillison, R. L. Ferris, K. Harrington, T. K. Sanchez, C. Baudelet, W. J. Geese, J. Shaw, R. Haddad

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)vi350
JournalAnnals of Oncology
StatePublished - Oct 1 2016
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this